Adial Pharmaceuticals, Inc. (ADIL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and ...
On Thursday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that the United States Patent and Trademark Office has ...
Nov. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment ...
Nov. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the ...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the recipient of a significant growth in short interest during the month of November.As of November 15th, there was short interest ...
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...